Avalo Therapeutics

web2

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatmen...

Stage

Undisclosed

Funding

Undisclosed

Team

0.0Mission ScoreFixed 0-100 scale

About

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Expert Insight

Avalo Therapeutics profile.

Expert Coverage

No published expert evaluations are available for this project yet.

Biotechnology & Medical ResearchHealthcare

0team

0evaluations

0subscribers